Consistent with its anti-angiogenic effects, Nintedanib therapy also reduced phosphorylation of RET, VEGFR2, and ERK1/2 in MTC tumors (Figure 4D). This evidence concerns the gene MAPK3 and medullary thyroid gland carcinoma.